SCHEMBL171986

SCHEMBL171986

CNC(=S)NC(=O)Cc1ccc(O)c(O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
MAPT P10636 5/20 0.50
GAA P10253 4/20 0.50
HIF1A Q16665 3/20 0.50
HSD17B10 Q99714 3/20 0.50
KDM4E B2RXH2 3/20 0.50
HPGD P15428 3/20 0.50
BLM P54132 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
TSHR P16473 2/20 0.50
NFKB1 P19838 2/20 0.50
THPO P40225 2/20 0.50
PMP22 Q01453 2/20 0.50
TRPV1 Q8NER1 1/20 0.50
RGS12 O14924 1/20 0.50
POLB P06746 1/20 0.50
APEX1 P27695 1/20 0.50
GNAI1 P63096 1/20 0.50
KMT2A Q03164 1/20 0.48
ERCC1 P07992 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10203658 0.84 TRPV1 (0.47) LMNAMAPTGAAHIF1AHSD17B10
SCHEMBL14015924 0.83 MAPT (0.60) LMNAMAPTGAAHIF1AHSD17B10
SCHEMBL17993489 0.81 KDM4E (0.53) LMNAMAPTGAAHIF1AHSD17B10
SCHEMBL14873200 0.79 LMNA (0.57) LMNAGAAHPGDTDP1KMT2A
SCHEMBL171948 0.78 KMT2A (0.78) LMNAMAPTGAAKDM4EHPGD
SCHEMBL171965 0.78 LMNA (0.55) LMNAGAAKDM4EHPGDTDP1
SCHEMBL10172598 0.77 LMNA (0.48) LMNAMAPTHIF1AHSD17B10HPGD
SCHEMBL171909 0.77 CRHBP (0.58) LMNAMAPTGAATDP1POLB
SCHEMBL14817526 0.76 SIGMAR1 (0.47) LMNAMAPTGAAKDM4EKMT2A
SCHEMBL169824 0.75 TDP1 (0.76) LMNAGAAKDM4ETDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018378-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2015-04-28 US disclosed
US-8907091-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-8846927-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-09-30 US disclosed
US-8569503-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2013-10-29 US disclosed
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2013-06-27 US disclosed
EP-2426108-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors MethylGene Inc. (CA) 2012-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET LMNA 4752/4885MAPT 1806/4885GAA 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.